Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -269.20% is 163% below its 5-year average of -102.54%, near the low end of its 5-year range (-269.20%–-32.71%).
78.83% below its 12-month average of -150.53%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -23.39%.
RETURN ON ASSETS (ROA)
-269.20%
RETURN ON ASSETS (ROA) AVG TTM
-150.53%
RETURN ON ASSETS (ROA) AVG 3Y
-111.73%
RETURN ON ASSETS (ROA) AVG 5Y
-102.54%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-78.83%
CURRENT VS 3Y AVG
-140.94%
CURRENT VS 5Y AVG
-162.54%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-734.34%
vs the sector median at left
Jasper Therapeutics, Inc.
Market Cap
$9.10M
Return on Assets (ROA)
-269.20%
TTM Avg
-150.53%
3Y Avg
-111.73%
5Y Avg
-102.54%
Market Cap
$9.05M
Return on Assets (ROA)
-157.56%
TTM Avg
-309.44%
3Y Avg
-441.71%
5Y Avg
-440.28%
Market Cap
$8.82M
Return on Assets (ROA)
-6.36%
TTM Avg
-31.97%
3Y Avg
-31.64%
5Y Avg
-61.82%
Market Cap
$9.50M
Return on Assets (ROA)
-73.89%
TTM Avg
-61.17%
3Y Avg
-50.83%
5Y Avg
-128.36%
Market Cap
$9.71M
Return on Assets (ROA)
-52.23%
TTM Avg
-58.24%
3Y Avg
-82.00%
5Y Avg
-104.09%
Market Cap
$9.75M
Return on Assets (ROA)
-108.85%
TTM Avg
-94.23%
3Y Avg
-71.21%
5Y Avg
-107.74%
Market Cap
$9.83M
Return on Assets (ROA)
-115.57%
TTM Avg
-131.41%
3Y Avg
-121.81%
5Y Avg
-149.86%
Market Cap
$9.86M
Return on Assets (ROA)
-57.74%
TTM Avg
-114.78%
3Y Avg
-140.32%
5Y Avg
-142.57%
Market Cap
$8.33M
Return on Assets (ROA)
-23.11%
TTM Avg
-173.03%
3Y Avg
-145.25%
5Y Avg
-97.33%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | $9.10M | -269.20% | -150.53% | -111.73% | -102.54% |
| SeaStar Medical Holding Corporation (ICU)vs › | $9.05M | -157.56% | -309.44% | -441.71% | -440.28% |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $8.82M | -6.36% | -31.97% | -31.64% | -61.82% |
| Ainos, Inc. (AIMD)vs › | $9.50M | -73.89% | -61.17% | -50.83% | -128.36% |
| Satellos Bioscience Inc. (MSLE)vs › | $9.71M | -52.23% | -58.24% | -82.00% | -104.09% |
| MetaVia Inc. (MTVA)vs › | $9.75M | -108.85% | -94.23% | -71.21% | -107.74% |
| NeuroOne Medical Technologies Corporation (NMTC)vs › | $9.83M | -115.57% | -131.41% | -121.81% | -149.86% |
| Valion Bio, Inc. (VBIO)vs › | $9.86M | -57.74% | -114.78% | -140.32% | -142.57% |
| Healthcare Triangle, Inc. (HCTI)vs › | $8.33M | -23.11% | -173.03% | -145.25% | -97.33% |
| Medicus Pharma Ltd. Common Stock (MDCX)vs › | $10.06M | -204.84% | -224.84% | -332.29% | -789.37% |
ROA
-269.2%
ROE
-2248.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -211.86% |
| 2024-12-31 | -89.20% |
| 2023-12-31 | -67.94% |
| 2022-12-31 | -77.92% |
| 2021-12-31 | -32.71% |
| 2020-12-31 | -135.59% |
| 2019-12-31 | -18.33% |
